{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":9,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07595874\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NEST3","nct_id":"NCT07595874","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nest3-nct07595874. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"NEST3","arms":[{"description":"Patients receive botensilimab IV, over 30 minutes, on day 1 and balstilimab IV, over 30 minutes, on days 1, 15, 29 and 43 in the absence of disease progression or unacceptable toxicity. 5-16 weeks later, patients then undergo standard of care resection surgery. Patients undergo CT scan and/or MRI and blood sample collection throughout the study.","label":"Treatment (botensilimab and balstilimab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"conditions":["Advanced Colon Adenocarcinoma","Advanced Colorectal Adenocarcinoma","Advanced Rectal Adenocarcinoma","Stage IIB Colon Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Colon Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8"],"enrollment":{"count":100,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Balstilimab","type":"BIOLOGICAL"},{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Botensilimab","type":"BIOLOGICAL"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"}],"last_update":"2026-07-01","lead_sponsor":"City of Hope Medical Center","official_title":"A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Two-year disease-free survival rate","timeFrame":"At 2 years post enrollment"}],"references":[],"start_date":{"date":"2026-12-27","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","url":"https://clinicaltrials.gov/study/NCT07595874"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nest3-nct07595874"}